medigraphic.com

2003, Number 4

<< Back Next >>

Rev Mex Anest 2003; 26 (4)

Análisis de la eficacia antinociceptiva de Parecoxib en ratas con artritis de tipo gota

Arzubide DG, López MFJ, Guevara LU, Lara SA, Acquart AZ, Aguirre LF, Lecona PM, Infante G, Tamayo VA

Language: Spanish
References: 35
Page: 188-193
PDF size: 159.33 Kb.


ABSTRACT

This study is aim to evaluate the antinociceptive effect of parecoxib sodium at different doses. We induced arthritic pain in Wistar rats and force them to walk in a rotatory drum. An electrode was attached to each hind paw between the plantar pads. Rats were allowed to recover from anesthesia and then were placed on a stainless steel cylinder of 30 cm of diameter. The time of contact of each hind paw was recorded by plantar electrodes. Data are expressed as the functionality index (FI). Which is the time of contact of the injected limb divided by the time of contact of the control left limb multiplied by 100. When FI was “zero” we administrated the agent intravenous and recorded each half an hour by two minutes the next 4 hours. Results: We studied a total of 45 animals. The doses were calculated with a logarithmic base in increasing order. The antinociceptive efficacy was estimated having two bases: The temporal course curved and dosage-answer curved. The temporals courses showed an increment in agreement with the increment dosages from the agent. The antinociceptive efficacy was observed half an hour after the administration and it was maintained across time. Discussion: We did not observe adverse effects by parecoxib in studied dosage. We observed that it is an agent that is necessary to increase significance the doses for increase the antinociceptive effect and moreover it showed a ratio dose-dependent. We considered that the results from this study are not conclusive because is necessary to have more experiments with parecoxib in comparative shapes.


REFERENCES

  1. Paul J. Desjardins, DMD, Evie Grossman, Michael E. Kus. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has Analgesic efficacy when administered preoperatively. Anesth Analg 2001;93:721-727.

  2. López Muñoz F, Ventura MR, M. Díaz, GI, Hernández P. Role of COX-1 and COX-2 synthesized prostaglandins in a Rat Model of Arthritic Pain. Drug Development 2002;51:253-259.

  3. Anderson GD, Hausser SD, McGarity KL, Bremer ME. Selective inhibition of cyclooxygenase COX-2 reverses inflammation and expression of COX-2 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-2679.

  4. Boynton CS, Dick CF, Mayor GH. NSAID: An overview. J Clin Pharmacol 1988;28:512-517.

  5. Carson JL, Strom BL. The gastrointestinal side effects of the NSAID. J Clin Pharmacol 1988;28:554-559.

  6. Castañeda HG, Castillo-Méndez MS, López Muñoz FJ. Potentiation by caffeine of the analgesic effect of aspirin in the pain-induced functional impairment model in rat. Can J Physiol Pharmacol 1994;72:1127-1131.

  7. López Muñoz FJ. Surface of synergistic interaction between dipyrone and morphine in the PIFIR model. Druf Dev Res 1994;33:26-32.

  8. López Muñoz FJ, Salazar LA, Castañeda-Hernández G, Villareal JE. A new model to assess analgesic activity: “pain induced functional impairment in the rat” (PIFIR). Drug Dev Res 1993;28:169-175.

  9. López Muñoz FJ, Castañeda-Hdez G, Villalón CM, Terrón JA. Analgesic effects of combinations containing opioid drugs with either aspirin or acetaminophen in the rat. Drug Dev Res 1993;29:299-304.

  10. López Muñoz FJ, Villalón CM, Terrón JA, Salazar LA. Analgesic interaction produced by dipyrone and either morphine or dextropropoxyphene in PIFIR. Drug Dev Res 1994:32:50-57.

  11. López Muñoz FJ, Castañeda Hdez G, Flores-Murrieta FJ, Granados SV. Effect of caffeine coadministration of nitric oxide synthesis inhibition on the antinociceptive action of ketorolac. Eur J Pharmacol 1996;308:275-277.

  12. López Muñoz FJ, Ventura MR, Díaz J, Fdez A. Antinociceptive effects of ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. J Clin Pharmacol 1998;38:11s-21s.

  13. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.

  14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat New Biol 1971;231:232-235.

  15. Aguirre-Bañuelos P, Castañeda Hdez G, López Muños FJ, Granados Soto V. Effects of coadministration of caffeine and either adenosine agonist or cyclic nucleotids on ketorolac analgesia. Eur J Pharmacol 1999;377:175-182.

  16. Bjorkman R. Central antinociceptive effects of non-steroidal antiinflammatory drugs and paracetamol. Experimental studies in rat. Acta Anaesth Scand 1991;39(Suppl. 103):4-44.

  17. Fort J. Celecoxib, a cox-2 specific inhibitor: the clinical data. Am J Orthop 1999;28(Suppl. 2):13-18.

  18. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul Clark MJ. Inducible cyclooxigenase may have anti-inflammatory properties. Nat Med 1999;5:698-701.

  19. Raskins JB. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am J Med 1999;106:3s-12s.

  20. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Lea and Feiberg, Philadelphia 1989.

  21. Salazar LA, Ventura MR, López Muñoz FJ. Synergistic antinociceptive interaction between aspirin and tramadol, the atypic opioid analgesic, in the rat. Drug Dev Res 1995;36: 119-124.

  22. Ryn JV, Pairet M. Clinical experience with cyclooxygenase-2 inhibitors. Inflam Res 1999;48:247-254.

  23. Wallace JL. Distribution and expression of cyclooxigenase (COX) isoenzymes, their physiological roles, and the categorization of NSAID. Am J Med 1999;107:11s-16s.

  24. Moore PA, Werther JR, Seldin EB, Stevens CM. Analgesic regimens for third molar surgery: pharmacology and behavioral considerations. J Am Dent Assoc 1986;113:739-44.

  25. Wright A. Recent concepts in the neurophysiology of pain. Man Ther 1999;4:196-202.

  26. Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 1992;44:14-29.

  27. Daniels SE, Kuss MJ, Mehlisch DR, Bauman A, Karim A, Hubbard R. Pharmacokinetic and efficacy evaluation of IV parecoxib in a postsurgery pain dental model. Clin Pharmacol Ther 2000;67:P1- 8 (Abstract).

  28. Kenaan CA, Bikhazi GB, Deepika K, Calfa CI, Ortiz K. Analgesy activity and safety of parecoxib in post-surgical patients: An interim report. Anesth Analg 2000;92:s257.

  29. Noveck RJ, Kuss ME, Qian J, North J, Hubbard RC. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function. Reg Anesth Pain Med 2002;26(suppl 1):19.

  30. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, Inc. 1995:293-296.

  31. Mattok GL. Premarketing biopharmaceutical requirements. Drug Information J 1988:22:143-148.

  32. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956;91:95-101.

  33. Carr DB, Goudas LC. Acute pain. Lancet 1999;12;353:2051-8.

  34. Susan MCh, Karen LG. Parecoxib sodium. Drugs 2001;61(8):1133- 1141.

  35. Andra Ibrahin, MD; Sang Park, MD; Jennifer Fieldman, BS; Aziz Karim, Ph. Effects of parecoxib a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 2002;96:87-95.




2020     |     www.medigraphic.com